Takeaways: Roche’s dual-formulation (IV and SC) authorization for Lunsumio (mosunetuzumab) in Canada creates flexible, fixed-duration access for relapsed/refractory follicular lymphoma...
Home / complete response rate
Browsing Tag: complete response rate
Social Icons
Featured Posts
1
AbbVie’s Boey Approved in Canada for Glabellar Lines
June 24, 20262
Roche’s Itovebi Moves Closer to Public Access in Canada
June 24, 20263
